Limits...
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models.

Hijona E, Banales JM, Hijona L, Medina JF, Arenas J, Herreros-Villanueva M, Aldazabal P, Bujanda L - Cancer Cell Int. (2012)

Bottom Line: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%).The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%).The combination of pravastatin + sorafenib were more effective than Sorafenib alone.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Gastroenterology, Donostia Hospital, Instituto Biodonostia, University of the Basque Country EHU/UPV, Ciberehd, San Sebastián, Spain. Eli.hijonamuruamendiaraz@osakidetza.net.

ABSTRACT

Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.

Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.

Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).

Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.

No MeSH data available.


Related in: MedlinePlus

Levels of AST, ALT, GGT and ALP in the different groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298718&req=5

Figure 6: Levels of AST, ALT, GGT and ALP in the different groups.

Mentions: We also observed significantly lower levels of GOT, GPT, GGT and alkaline phosphatise (ALP) in the three experimental groups. Moreover, this decrease was more significant in the pravastatin groups (D 619.5 U/L; 271 U/L; 58.35 U/L; 190 U/L) (P 117.5 U/L;43.5 U/L;7 U/L;129 U/L) (S 147 U/L;59 U/L;23 U/L;172 U/L) (P + S 142 U/L;59.5 U/L;7 U/L;137 U/L) (p < 0.05) (Figure 6).


Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models.

Hijona E, Banales JM, Hijona L, Medina JF, Arenas J, Herreros-Villanueva M, Aldazabal P, Bujanda L - Cancer Cell Int. (2012)

Levels of AST, ALT, GGT and ALP in the different groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298718&req=5

Figure 6: Levels of AST, ALT, GGT and ALP in the different groups.
Mentions: We also observed significantly lower levels of GOT, GPT, GGT and alkaline phosphatise (ALP) in the three experimental groups. Moreover, this decrease was more significant in the pravastatin groups (D 619.5 U/L; 271 U/L; 58.35 U/L; 190 U/L) (P 117.5 U/L;43.5 U/L;7 U/L;129 U/L) (S 147 U/L;59 U/L;23 U/L;172 U/L) (P + S 142 U/L;59.5 U/L;7 U/L;137 U/L) (p < 0.05) (Figure 6).

Bottom Line: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%).The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%).The combination of pravastatin + sorafenib were more effective than Sorafenib alone.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Gastroenterology, Donostia Hospital, Instituto Biodonostia, University of the Basque Country EHU/UPV, Ciberehd, San Sebastián, Spain. Eli.hijonamuruamendiaraz@osakidetza.net.

ABSTRACT

Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models.

Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels.

Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L).

Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.

No MeSH data available.


Related in: MedlinePlus